Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Wesley0428 who wrote (572)	2/18/1998 2:31:00 PM
From: William J. Leiby	Read Replies (1) of 849

Wesley: Thanks for the report. But, I have to admit I am somewhat disappointed. I had a conversation with someone in the company back in the fall in which it was noted that if they didn't get approval for NuMa within the first qtr, THEY would be disappointed. (Did management speak of NuMa' acceptance and the market in Europe)? In that conversation, it was also suggested to me that the idea of NMP-22 as a screening tool was on the back burner. Looks like strategy and plans may be a bit more fluid that I perceived. As far as the cervical test, it seems it will not have the significance I was hoping for. The area where I'm most disappointed is the breast test. A report I read back in November indicated that clinical trials were scheduled to begin this year and that sales of this test would commence in Europe at the end of this year! If the report is true then the co. must have started the preclinical trials or they're ready to go. How long should the preclinical take? Someone cheer me up. Regards, Bill

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next